Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
| | |||
Addex Pharmaceuticals |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
Collaboration to discover, develop and sell compounds that modulate allosterically GPCRs for treating various CNS diseases |
Addex gets an up-front fee and research funding for two years; it also could earn milestone and royalty payments (1/17) |
Adenosine |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
Collaboration and option deal to further develop A2B adenosine receptor antagonists for Type II diabetes, asthma and other disorders |
Ortho-McNeil gets a one-year exclusive option to certain compounds, and will fund a one-year research alliance; if the option is exercised Adenosine would get an option fee, research support and potential milestone and royalty payments (1/19) |
Affectis |
Mitsubishi Pharma Corp. (Japan) |
Affectis will use its target validation technology and animal models in a deal to develop drugs for affective disorders |
Affectis (formerly Neuronova AG) will work on Mitsubishi targets in anxiety and depression; terms of the deal were not disclosed (2/7) |
Affymetrix |
Veridex LLC (unit of Johnson & Johnson) |
Veridex gained nonexclusive rights to Affymetrix's GeneChip technology |
Veridex will use the technology to develop in vitro diagnostics for cancer; terms of the deal were not disclosed (12/28) |
Albany |
Eli Lilly and Co. |
AMRI will provide chemistry research on projects in undisclosed areas identified by Lilly |
Terms of the fee-for-service deal were not disclosed; the new deal continues a relationship between the companies that began in 1998 (2/8) |
Albany |
Alcon Research Ltd. |
AMRI will screen its natural product collections under a two- year deal to discover and develop ophthalmic drugs |
AMRI will get service and library-access fees, as well as potential milestone payments and sales royalties (1/7) |
Allergy |
Allerpharma Inc. (Canada) |
Allerpharma got rights to market AT's four-shot allergy vaccine Pollinex Quattro in Canada |
They will collaborate on further development, and Allerpharma gets rights to sell AT's existing ragweed allergy in Canada; AT gets up to $15M in milestone payments and royalties on sales (1/5) |
Alliance |
LEO Pharma A/S (Denmark) |
LEO plans to license rights to develop and sell Oxygent in Europe and Canada |
Alliance subsidiary PFC Therapeutics LLC is entitled to up-front, milestone and royalty payments, subject to completion of due diligence by LEO (1/3) |
Alnylam |
Medtronic Inc. |
Collaboration to develop drug- device combinations incorporating RNAi therapeutics for treating neurodegenerative disorders |
If they enter product development after an initial program, Alnylam would receive an equity investment and could get additional payments, as well as milestones and royalties for each product developed (2/9) |
Ambit |
Bristol-Myers Squibb Co. |
Ambit will use its kinase platform to characterize the specificity of certain BMS compounds |
Terms of the deal were not disclosed (1/17) |
Ambit |
GlaxoSmithKline plc (UK) |
Ambit will use its platform to profile kinase target specificity of certain GSK compounds |
Terms of the deal were not disclosed (1/17) |
Ambit |
Pfizer Inc. |
Ambit will apply its Reverse Screening technology to identify and characterize protein targets of certain Pfizer compounds |
Terms of the deal were not disclosed (1/17) |
Amphora |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
They entered a multiyear |
Ortho-McNeil gets exclusive rights to existing Amphora compounds as well as new ones discovered during the collaboration; Amphora gets a license fee, research funding and potential milestone and royalty payments (1/10) |
Argenta |
Novartis AG (Switzerland) |
Two-year drug discovery collaboration in the area of diabetes |
Up to 18 Argenta scientists will work on the Novartis program; terms of the deal were not disclosed (1/24) |
Ariad |
Medinol Ltd. (Israel) |
Deal to develop stents and other devices to deliver Ariad's mTOR inhibitor AP23573 in angioplasty procedures |
Ariad is eligible to receive license fees and milestone payments of up to $39.25M, if two products are developed, plus royalties on product sales (1/27) |
Arena |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
Worldwide collaboration to further develop compounds for Type II diabetes and other disorders |
Arena gets $17.5M up front and could receive up to $295M in development and sales milestones for each compound developed; Arena also gets research funding of $4.8M over two years, and would get low-double-digit royalties on sales (12/21) |
Avexa Ltd. |
Shire Pharmaceuticals Group plc (UK) |
Avexa licensed rights to the HIV compound SPD754 worldwide except North America |
The deal includes reciprocal royalty provisions; Shire took an A$2M equity position in Avexa, and has an option to acquire 4M more shares following successful completion of ongoing Phase IIb trials (1/17) |
Axxam Srl* |
CyBio AG (Germany) |
Deal to develop and sell technologies for drug discovery using automated luminescence screening systems |
They each will contribute technology to the effort; terms were not disclosed (2/8) |
Basilea |
Cilag AG International (unit of Johnson & Johnson) |
Worldwide, exclusive deal to develop and market ceftobiprole, Basilea's Phase III broad-spectrum antibiotic |
Basilea will get up-front and milestone payments of up to $304M; it also would get double-digit royalties on sales (2/3) |
BioDelivery |
Sigma-Tau Group (Italy) |
BDSI will apply its Bioral nanocochleate delivery technology to formulate up to four Sigma-Tau compounds |
Sigma-Tau is buying $250,000 of BDSI stock at $4.25 per share share and up to $1.25M more if milestones are achieved; BDSI also would get royalties on sales (1/20) |
BioImage A/S* |
Boehringer Ingelheim GmbH (Germany) |
BI gained rights to use BioImage's Redistribution technology in drug discovery research |
The technology is used for studying intra- cellular signaling events; terms of the deal were not disclosed (1/31) |
Cerep SA |
Sanofi Synthélabo Recherche (France) |
Cerep will synthesize thousands of compounds for Sanofi |
The companies also renewed a discovery deal signed in 1997 for 2005; terms were not disclosed (2/14) |
Cerus Corp. |
BioOne Corp. (Japan) |
Letter of intent calls for BioOne to sell the the Intercept Blood System for plasma in much of Asia |
Cerus gets $3M upon signing the letter of intent; the companies last year entered a a similar deal covering the system for platelets in Japan (1/5) |
Cerus Corp. |
Chugai Pharmaceutical Co. Ltd. (Japan) |
Cerus acquired an exclusive license in the field of cancer vaccines to Chugai's patent on the DNA sequence of mesothelin |
Cerus is paying up-front and potential milestone and royalty payments for rights to the antigen, which it will use to develop immunotherapies (12/22) |
ChondroGene |
Pfizer Inc. |
Two-year collaboration to identify therapeutic targets and biomarkers for treating and diagnosing osteoarthritis |
The deal continues work in two research programs the companies began in October 2002; the deal is valued at up to $7.35M; the initial deal was worth $4.7M (12/21) |
Chromos |
Pfizer Inc. |
They will develop cell lines using the Artificial Chromosome Expression system for the production of Pfizer recombinant proteins |
Pfizer will pay for the work and evaluate the performance of the engineered cell lines; terms of the deal were not disclosed (12/17) |
Crucell NV (the |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Roche got a license to use the PER.C6 cell line for production of monoclonal antibody products and a specific undisclosed protein |
Roche will provide a research license payment, annual maintenance fees and research funding; further terms were not disclosed (2/16) |
Dendritic Nano-Technologies |
The Dow Chemical Co. |
DNT and Starpharma acquired Dow's patent portfolio in the field of dendrimers (nanostructures) | Dow gained a significant equity stake in DNT; Starpharma, which already owned 42% of DNT, will make an additional equity investment in DNT in exchange for exclusive rights to polyvalent, dendrimer-based pharmaceutical applications (1/25) |
Diversa |
Merck & Co. Inc. |
Diversa will apply its MedEv platform in a collaboration to develop therapeutic antibodies for an undisclosed target |
Diversa gets an up-front payment and research funding; further terms were not disclosed (1/11) |
EiRx |
Merck & Co. Inc. |
EiRx will perform research over three months to demonstrate its technology to Merck |
EiRx will use it siRNA delivery technology, which is used for validation of drug targets; terms were not disclosed (2/7) |
Entelos Inc.* |
Organon International (the Netherlands) |
They extended rheumatoid arthritis collaboration to develop and sell therapeutics directed at targets identified by Entelos |
They entered the deal after three years of research; Organon gets exclusive rights to the targets and access to Entelos research capabilities; Entelos gets co-promotion and co- commercialization rights (2/15) |
Faustus |
Bioaccelerate Inc. |
Collaboration to develop eight Faustus cancer agents, five of which are in clinical development |
Bioaccelerate will fund further development; other terms were not disclosed (12/14) |
4SC AG* |
Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) |
4SC will apply its discovery platform to develop drug candidates against two specific targets from SKK |
4SC gets research funding over several years and is eligible for research and clinical milestone payments, as well as royalties on any resulting sales (2/15) |
Galapagos |
GlaxoSmithKline plc (UK) |
GSK exclusively licensed drug targets from Galapagos' asthma and allergy program |
They also entered a three-year deal to discover further targets in asthma and inflammatory diseases; Galapagos gets an up-front payment, research funding and potential milestone payments (1/5) |
Galenea |
Otsuka Pharmaceutical Co. Ltd. (Japan) |
Deal to discover drugs for treating central nervous system diseases |
Otsuka will make an equity investment and pay five years of R&D funding in exchange for rights to targets and drug candidates; Galenea also can get milestone and royalty payments, and would have an option to participate in profit sharing (2/16) |
Gamida-Cell |
Teva Pharmaceutical Industries Ltd. (Israel) |
Teva exercised an option to enter a joint venture to develop and sell StemEx for leukemia and lymphoma |
Teva will invest up to $25M in the joint venture; it held the option as part of an investment in Gamida-Cell in 2003 (2/16) |
GB |
Chiesi Farmaceutici SpA (Italy) |
GB licensed Chiesi's CHF1512, a methyl-ester of levodopa combined with carbidopa |
The product is registered in Italy; Chiesi gained an equity stake in GB; terms of the exclusive license to the Parkinson's disease drug were not disclosed (1/27) |
GeneGo Inc.* |
GlaxoSmithKline plc (UK) |
GSK licensed use of the MetaBase biology and chemistry platform |
GSK will apply MetaBase to drug discovery efforts, and integrate content with its internal informatics systems; terms were not disclosed (1/31) |
GeneGo Inc.* |
Altana Pharma AG (Germany) |
Altana licensed use of the MetaCore systems biology platform |
Terms of the deal were not disclosed (1/21) |
Genfit SA* |
Pierre Fabre Group (France) |
Three-year collaboration to develop a new family of compounds for cardiovascular and other diseases |
Genfit will get research fees and potential milestone and royalty payments; the deal is separate from their ongoing collaboration from 2001 (1/3) |
Genomatica |
Kyowa Hakko Kogyo Co. Ltd. (Japan) |
Kyowa Hakko licensed Genomatica's modeling and simulation platform |
Genomatica is entitled to license fees and milestone payments; the technology will be used for producing high-quality fine chemicals (1/5) |
Gen-Probe Inc. (GPRO) |
bioMerieux SA |
bioMerieux exercised an option to develop diagnostic products for certain disease targets using Gen-Probe's ribosomal RNA technologies |
Gen-Probe gets a $4.5M license fee, while bioMerieux retains options to develop diagnostics for other disease targets by paying up to $3M more by the end of 2006 (1/20) |
Geron Corp. |
Cambrex Bio Science Walkersville Inc. |
Cambrex will develop and distribute cell lines that have been immortalized using Geron's telomerase technology |
Geron gets an up-front license fee and royalties on any sales, and retains all rights for the use of telomerized cells in therapeutic applications (1/11) |
Gilead |
Bristol-Myers Squibb Co. |
They established a joint venture to develop and sell a once-daily combination HIV product |
The product combines Gilead's Truvada and BMS' Sustiva; they will share costs and revenues (12/20) |
Helix BioMedix |
Smith & Nephew plc |
Smith & Nephew got a right of first offer to license rights to certain wound-related indica-tions for the peptide HB50 |
Smith & Nephew will provide development input; terms of the deal were not disclosed (1/21) |
Human |
Mitsubishi Pharma Corp. (Japan) |
Collaboration to find a biomarker for phospholipidosis, a lipid storage disorder |
HMT will apply its metabolome technology in the deal, terms of which were not disclosed (2/14) |
ImClone |
Centocor Inc. (unit of Johnson & Johnson) |
ImClone licensed patents covering various aspects of antibody technology and uses of EGFR antibodies |
The license relates to ImClone's approved product Erbitux and its investigational drug IMC-11F8; terms were not disclosed (1/26) |
Immunicon |
Pfizer Inc. |
They extended for a second time a deal to develop reagents to detect certain antigens on circulating tumor cells |
The agreement, originally entered into in February 2003, was extended to February 2006; Immunicon will get undisclosed payments (12/21) |
ImmunoGen |
Centocor Inc. (unit of Johnson & Johnson) |
Centocor got worldwide rights to use an ImmunoGen maytansinoid cell-killing agent with a Centocor cancer antibody |
ImmunoGen gets an up-front payment of $1M and up to $42.5M in milestone payments, as well as research payments and royalties on any resulting sales (12/28) |
Infinity |
Johnson & Johnson Pharmaceutical Research and Development LLC |
J&J got nonexclusive access to Infinity's compound collection to identify drug leads |
Infinity received an undisclosed up-front fee and an equity investment (1/6) |
Infinity |
Novartis AG (Switzerland) |
Two-year deal to design small molecules to be synthesized by Infinity using its chemical technology platform |
Infinity received an equity investment and is expected to receive more than $10M in additional fees; each company can use the resulting compound collection in its own discovery efforts (1/5) |
Inpharmatica |
Pfizer Inc. |
Pfizer gained access to parts of Inpharmatica's PharmaCarta platform |
The deal for target-selection technology is in addition to Pfizer's Biopendium subscription; terms were not disclosed (1/25) |
Jerini AG* |
Alcon Research Ltd. |
Multitarget collaboration to develop drugs for ophthalmology indications |
Jerini gets up-front and license fees as well as personnel funding, along with potential milestone and royalty payments (1/19) |
Juvantia |
Alcon Research Ltd. |
Deal giving Alcon access to Juvantia compounds, which it will evaluate for treating ophthalmic diseases |
Alcon has the option to enter into a development and license agreement; terms of the deal were not disclosed (1/13) |
Lexicon |
Johnson & Johnson Pharmaceutical Research & Development LLC |
J&J got nonexclusive rights to patents covering gene-targeting technologies for generating knockout mice |
J&J can use the "isogenic DNA" and "positive-negative selection" technologies for research purposes under undisclosed terms (12/23) |
MAT Biotech* |
Laboratoires Servier (France) |
Collaboration to develop antibody products for various cancers |
MAT's anti-ferritine monoclonal antibody AMB8LK will be coupled to a cytotoxic molecule from Servier; terms were not disclosed (1/20) |
Medicago |
Bayer CropScience AG (Germany) |
Deal to assess the feasibility of using Medicago technology for producing an undisclosed human therapeutic protein |
The deal involves the Proficia Protein Technology, which entails use of alfalfa plants; terms of the deal were not disclosed (1/31) |
Millennium |
UCB Pharma (Belgium) |
Deal to develop and sell antibodies generated from two Millennium targets: a co-stimulatory molecule and a chemokine receptor |
UCB will be responsible for development and costs through Phase II trials; Millennium is entitled to milestone payments, and retains the option to co-develop and co-commercialize products under a cost- and profit-sharing arrangement (1/25) |
Morphochem |
Alcon Research Ltd. |
Collaboration to develop small-molecule drugs against ophthalmic targets |
Morphochem will apply its MolMind technology to make libraries for certain Alcon targets in return for research payments and potential milestones and royalties; Alcon gets rights to any resulting products for ophthalmic and nasal applications (1/10) |
MorphoSys |
Centocor Inc. (unit of Johnson & Johnson) |
They extended through 2007 a collaboration to develop fully human antibodies in a range of indications |
The five-year deal was to end in December 2005; the extension calls for MorphoSys to get an up-front payment and increased research funding (12/23) |
MorphoSys |
Schering AG (Germany) |
They extended for at least two years a collaboration to develop antibody therapeutics and in vivo diagnostics; Schering has access to the HuCAL Gold technology |
The December 2001 deal was extended at least through 2006; MorphoSys gets annual license fees, research funding, other license fees and potential milestone and royalty payments; Schering also gets exclusive licenses for several therapeutic antibody programs from their collaboration (12/20) |
NascaCell IP |
Boehringer Ingelheim GmbH (Germany) |
Collaboration on aptamer-based target validation and drug discovery |
NascaCell will provide BI custom aptamers for therapeutic targets; terms were not disclosed (2/16) |
Nektar |
Bayer HealthCare AG (Germany) |
Collaboration to develop an inhalable powder formulation of a novel form of ciprofloxacin for chronic lung infections |
Nektar, which will develop the powder and inhalation system, will receive funding for preclinical development, as well as potential milestone and royalty payments (1/25) |
NeoPharm |
Nippon Kayaku Co. Ltd. (Japan) |
Nippon Kayaku got exclusive Japanese rights to IL13-PE38QQR, a drug in trials for glioblastoma multiforme |
NeoPharm gets $2M up front and can earn $6M tied to approval in Japan; it also would be entitled to royalty and milestone payments based on sales (1/4) |
Neose |
BioGeneriX AG (Germany; part of the Ratiopharm Group) |
Three-month option deal to evaluate application of Neose's GlycoPEGylation technology to a marketed therapeutic protein |
Neose will get initial payments; if a license deal is signed, Neose would get additional up-front and research payments and could get up to $61.5M in milestone payments, as well as royalties on product sales (1/28) |
Neurochem |
Centocor Inc. (unit of Johnson & Johnson) |
Centocor got exclusive distribution rights for Fibrillex, which completed a Phase II/III trial in AA amyloidosis |
Neurochem gets up-front and regulatory- and sales-based milestone payments of up to $54M, as well as an escalating distribution fee based on sales; Neurochem kept rights in Canada, Switzerland, China, Japan, Taiwan and South Korea (12/22) |
New River |
Shire Pharmaceutical Group plc (UK) |
Collaboration covering New River's Phase III ADHD compound, NRP104; other indications also are covered |
New River gets $50 up front, and would get $50M upon acceptance of an NDA filing, up to $300M in milestones related to FDA- approved product labeling, and $100M if sales targets are hit; New River has a 25% co-promotion right in the U.S. (1/31) |
Oxford |
Undisclosed company |
The company gained use of Oxford's LentiVector gene-delivery system for research activities |
Oxford gets an up-front license payment and an annual maintenance fee; terms were not disclosed (2/1) |
Perlegen |
AstraZeneca plc (UK) |
Perlegen will conduct a high-density whole- genome association study for an undisclosed trait of interest |
Perlegen will genotype SNPs for the trait of interest and compare them to controls; terms of the deal were not disclosed (1/24) |
Perlegen |
Johnson & Johnson Pharmaceutical Research and Development LLC |
Pharmacogenomics deal to identify genetic markers for patient response to a J&J compound |
Perlegen will genotype single nucleotide polymorphisms and analyze results in the deal, terms of which were not disclosed (1/11) |
PharmaDesign |
Merck & Co. Inc. |
Merck licensed a GPCR peptide ligand library designed by PDI |
Merck made the deal with PDI representative Summit Pharmaceutical International Corp.; terms were not disclosed (2/2) |
Quark Biotech |
Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) |
Sanwa gained rights in Asia to Quark's Phase II compound BT16 for treating dyslipidemia |
Quark gets an up-front payment along with potential milestone and royalty payments (2/8) |
Rigel |
Pfizer Inc. |
Deal to develop products for allergic asthma and other respiratory diseases based on Rigel's preclinical compounds that inhibit IgE receptor signaling in mast cells |
Rigel gets an up-front payment along with potential milestone and royalty payments; Pfizer will make an equity investment in Rigel and be responsible for worldwide development and commercialization (1/20) |
Sangamo |
Pfizer Inc. |
Pfizer will assess Sangamo's zinc finger DNA-binding protein technology for use in mammalian cell-based protein pharmaceutical production |
Pfizer will fund research at Sangamo, which will generate cell lines and vector systems; terms were not disclosed (1/5) |
Sareum |
Undisclosed UK-based company |
Sareum will provide protein structure determination services for research against central nervous system diseases |
Sareum will receive undisclosed up-front and success payments from the deal (12/15) |
Sention Inc.* |
Merck & Co. Inc. |
Deal to develop a family of Merck compounds known as mGluR5 antagonists for treating mental retardation |
Sention gets access to preclinical candidates, which it will develop; it also can develop the drugs for Down syndrome and has an option in Huntington's disease (1/19) |
Serenex |
GlaxoSmithKline plc (UK) |
Serenex will use its Proteome Mining technology to provide information on compounds in development at GSK |
GSK scientists worldwide can submit compounds to Serenex for profiling against specific tissues and cell lines; terms of the deal were not disclosed (1/11) |
SurroMed |
PPD Inc. |
PPD is acquiring about all of the assets related to SurroMed's biomarker |
PPD will surrender for cancellation its shares of SurroMed preferred stock, will assume $3.4M of liabilities under capital leases and certain other liabilities related to business the biomarker business, and will guarantee repayment of a portion of a SurroMed bank loan up to $1.5M (1/17) |
TaiGen |
Procter & Gamble Pharmaceuticals |
Deal to further develop and sell P&G's non- lourinated quinolone antibiotic |
TaiGen will develop the product through Phase II, after which they may seek a partner; TaiGen gets rights in China, Taiwan, Korea and certain other countries (1/5) |
Tepnel Life |
Boehringer Ingelheim GmbH (Germany) |
BI will evlauate murine monoclonal antibodies generated by Tepnel subsidiary Diaclone Research |
Tepnel retains research and diagnostic rights to antibodies not developed as therapeutics by BI; terms were not disclosed (2/2) |
Transport |
GlaxoSmithKline plc (UK) |
Collaboration covering Transport's iontophoretic device/drug system for the delivery of the cold-sore drug acyclovir |
Transport gets an up-front license fee along with potential milestone and royalty payments, and some funding for upcoming Phase III trials; GSK gets exclusive rights in Europe, Australia, Latin America and South Africa (1/27) |
ViroLogic |
GlaxoSmithKline plc (UK) |
ViroLogic will use its HIV resistance testing technology to support GSK programs |
GSK will use ViroLogic's assays across its virology portfolio under the three-year, $7.5M deal (2/3) |
Xcellsyz Ltd.* |
Cambrex Bio Science Walkersville Inc. |
Cambrex purchased conditionally immortalized cell lines from Xcellsyz |
Terms of the deal were not disclosed (1/18) |
Xencor Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal under which Roche will use Xencor's XmAb technology on a Roche antibody against a cancer target |
Xencor will receive technology access and license fees, and is eligible to receive additional license fees along with milestone and royalty payments (1/12) |
Xencor Inc.* |
Chugai Pharmaceuticals Co. Ltd. (Japan) |
Deal under which Chugai will use Xencor's XmAb technology on one of its antibodies against a cancer target |
Xencor will receive technology access and license fees, and is eligible to receive additional license fees along with milestone and royalty payments (1/10) |
YM |
Shin Poong Pharmaceutical Co. (South Korea) |
Collaboration to expand development of YM's tesmilifene into gastric cancer |
Shin Poong will fund development and provide undisclosed up- front and potential milestone and royalty payments, and will launch a bridging study in breast cancer in Asia (1/31) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | |||
